Janssen applies to US and EU for subcutaneous Darzalex

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Picture)
(Image: Getty/Picture)

Related tags: Janssen, Halozyme, Darzalex, Roche, Herceptin

Janssen aims to expand the label of delivery in the US and EU for its product, Darzalex, to include subcutaneous delivery through the use of Halozyme’s technology.

Using Halozyme’s Enhanze drug delivery technology, Janssen has submitted an extension application to the European Medicines Agency (EMA) for the subcutaneous delivery of Darzalex (daratumumab) for the treatment of multiple myeloma.

The application to the EMA follows on from a similar application to the US Food and Drug Administration (FDA) for a biologics license application (BLA) for the subcutaneous formulation of Darzalex.

Currently, the treatment is approved for intravenous (IV) use but the subcutaneous formulation offers certain advantages over this form of delivery, such as by reducing infusion-related reactions and by cutting down on the time needed to deliver the treatment from hours to approximately five minutes, the company suggested.

The application for the new delivery method was supported by data from Phase II and Phase III trials, which demonstrated non-inferiority.

Craig Tendler, VP of clinical development and global medical affairs, oncology, at Janssen, said, "The Darzalex subcutaneous formulation showed non-inferiority to the existing IV formulation, both as a monotherapy and in combination with common background therapies, while administered with a considerably shorter infusion time.”

Janssen has previously invested in developing innovative means of drug delivery, such as in its partnership to develop Felden Therapeutics’ intracellular delivery technology​.

Halozyme’s tech pays off

Halozyme’s Enhanze drug delivery sees Darzalex co-formulated with recombinant human hyaluronidase PH20.

Genentech, a subsidiary of Roche, recently developed and received approval​ for a subcutaneous version of Herceptin (trastuzumab) through the use of Halozyme’s technology.

Previously, CEO of Halozyme, Helen Torley, told us that the subcutaneous version of Herceptin accounted for 60% of total volume of the drug sold.

Halozyme currently has licensing agreements with eight pharma and biotech companies for its technology.

Related news

Show more

Related products

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Fill Release at the Right Time in the Right Place

Fill Release at the Right Time in the Right Place

Gelita AG | 19-Sep-2018 | Technical / White Paper

From rapid release in the stomach for e.g. analgesics to enteric release for fills with unpleasant aftertaste – GELITA delivers the respective gelatine...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Related suppliers

Follow us

Products

View more

Webinars